Latest news with #FuzzyPanda
Yahoo
10 hours ago
- Business
- Yahoo
Tenet Healthcare Corp (THC) on the Spot over Medicare Fraud Allegations
Tenet Healthcare Corporation (NYSE:THC) is one of the 12 best healthcare stocks to buy now. On June 12, the stock was in recovery mode following a scathing report from Fuzzy Panda Research alleging that the company engaged in Medicare and Medicaid Fraud. Tenet Healthcare Corp (THC) on the Spot over Medicare Fraud Allegations A medical team performing minimally invasive surgery with a da Vinci Surgical System. The short seller alleges the company received over $167 million in excess Medicare outlier payments. It also alleges that the company accelerated outlier gaming activities after its five-year Corporate Integrity agreement ended. Fuzzy Panda also alleges that Tenet charged private jet costs to government programs and used undocumented immigrant newborns to secure Medicaid reimbursement. In the report, Fuzzy Panda alleged that the company could be hit by fines of between $675 million and $845 million. Over the past 20 years, the company has paid over $2.5 billion in fines. Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare company that operates a network of hospitals, ambulatory surgery centers, and other outpatient facilities. It also provides revenue cycle management services through its Conifer Health Solutions subsidiary. Tenet's mission is to deliver quality, compassionate care in their communities. While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None.
Yahoo
11 hours ago
- Business
- Yahoo
Tenet Healthcare Corp (THC) on the Spot over Medicare Fraud Allegations
Tenet Healthcare Corporation (NYSE:THC) is one of the 12 best healthcare stocks to buy now. On June 12, the stock was in recovery mode following a scathing report from Fuzzy Panda Research alleging that the company engaged in Medicare and Medicaid Fraud. A medical team performing minimally invasive surgery with a da Vinci Surgical System. The short seller alleges the company received over $167 million in excess Medicare outlier payments. It also alleges that the company accelerated outlier gaming activities after its five-year Corporate Integrity agreement ended. Fuzzy Panda also alleges that Tenet charged private jet costs to government programs and used undocumented immigrant newborns to secure Medicaid reimbursement. In the report, Fuzzy Panda alleged that the company could be hit by fines of between $675 million and $845 million. Over the past 20 years, the company has paid over $2.5 billion in fines. Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare company that operates a network of hospitals, ambulatory surgery centers, and other outpatient facilities. It also provides revenue cycle management services through its Conifer Health Solutions subsidiary. Tenet's mission is to deliver quality, compassionate care in their communities. While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-03-2025
- Business
- Yahoo
AppLovin Stock Tumbles After Short-Seller Report Alleging ‘Scammy' Practices
AppLovin shares plunged Thursday after short seller Muddy Waters alleged the adtech company engaged in 'scammy" practices. The report comes just weeks after other short sellers including Fuzzy Panda and Culper Research accused the company of fraudulent and deceptive practices. Thursday's losses brought shares into negative territory for the year. Still, they've nearly quadrupled in value over the last 12 months on anticipation of AI-driven (APP) shares plummeted Thursday after short seller Carson Block's Muddy Waters said it was taking a short position, alleging the adtech company engaged in 'scammy' practices. Shares lost about one-fifth of their value Thursday to close at $261.70, bringing them into negative territory for the year. Still, the stock has nearly quadrupled in value over the last 12 months on expectations it could benefit from growing demand for AI-powered advertising tools as the company reported strong revenue gains. Muddy Waters accused AppLovin of misappropriating data and violating key partner platforms' terms of service, among other things, and suggested backlash to its practices could hold back AppLovin's growth plans and lead its services to be blocked by partners and boycotted by clients. AppLovin did not immediately respond to a request for comment on the report. The report from Muddy Waters comes just weeks after other short sellers including Fuzzy Panda and Culper Research issued their own reports against AppLovin, accusing the company of engaging in fraudulent and deceptive practices. Read the original article on Investopedia
Globe and Mail
01-03-2025
- Business
- Globe and Mail
Short Sellers and Analysts Are Waging a War Over This ‘Strong Buy' AI Stock. Should You Buy or Sell Shares Now?
Valued at a market capitalization of $112 billion, AppLovin (APP) is a mobile technology company that helps businesses grow their customer base. Its services include mobile advertising, data analytics, and marketing. The tech stock went public in April 2021 and has since returned close to 400%, crushing broader market returns comfortably. However, it also trades 37% below its all-time highs due to broader market weakness and a couple of short-seller reports. On Wednesday, Feb. 26, AppLovin stock fell by 12% after two short-seller reports questioned the legitimacy of its AI-powered AXON advertising software, which helped make it the top-performing tech stock of 2024. Fuzzy Panda called AXON 'the nexus of a House of Cards' built on fraudulent advertising tactics, claiming AppLovin is stealing data from Meta (META) and exploiting consumers and their data in violation of Google (GOOG) (GOOGL) and Apple (AAPL) App Store policies. Culper Research alleged that AppLovin's gaming success stems from 'systematic exploitation of app permissions' to 'force-feed silent, backdoor app installations.' Meanwhile, AppLovin called the reports 'littered with inaccuracies' and suggested they were timed to prevent the company from responding with financial performance data. AppLovin Continues to Grow Rapidly AppLovin announced a strategic pivot to become a pure advertising platform during its Q4 earnings call, revealing plans to divest its entire Apps business for approximately $900 million. CEO Adam Foroughi described the quarter as 'our most foundational period since the AXON upgrade in 2023,' highlighting the company's successful expansion beyond gaming advertisements. AppLovin reported impressive Q4 results, with total revenue increasing 44% year-over-year to $1.37 billion and adjusted EBITDA growing 78% to $848 million. The Advertising segment generated $999 million in revenue with a 78% adjusted EBITDA margin, while free cash flow reached $695 million, up 105% from the previous year. AppLovin's platform reaches over 1 billion people daily through mobile games, with engagement times comparable to social networks. What's Next for the Tech Stock? AppLovin expects advertising revenue in Q1 to range between $1.03 billion and $1.05 billion, with adjusted EBITDA between $805 million and $825 million. Its management highlighted 'adjusted EBITDA per employee' as a key metric going forward, reporting approximately $3 million per employee in Q4 for the Advertising business. The strategic shift positions AppLovin to compete more broadly in the global advertising economy. Foroughi expresses confidence that the company is 'building a platform with the potential to transform global marketing.' Wall Street expects AppLovin to increase sales from $4.70 billion in 2024 to $5.8 billion in 2025. Comparatively, adjusted earnings per share are forecast to expand from $4.53 per share in 2024 to $6.56 per share in 2025. Its free cash flow is expected to grow from $2.1 billion in 2024 to $2.9 billion in 2025. So, APP stock might seem expensive, priced at 49x forward earnings and 38.6x forward FCF. However, its lofty valuation is supported by strong growth estimates. Of the 19 analysts covering AppLovin stock, 15 recommend 'Strong Buy' and four recommend 'Hold.' The average target price for APP stock is $501.37, indicating upside potential of 55% from current levels. On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
